Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEARCA:DBVNASDAQ:EGRXOTCMKTS:HIPHNASDAQ:PASG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDBVInvesco DB G10 Currency Harvest Fund$25.41$25.41$24.25▼$28.40$25.41M0.2327,852 shsN/AEGRXEagle Pharmaceuticals$3.00+3.6%$2.23$1.50▼$3.00$38.96M0.838,193 shs620 shsHIPHAmer Prem Water$0.00$0.00▼$0.00N/A2.0650,164 shs116,200 shsPASGPassage Bio$0.43-6.1%$0.38$0.26▼$1.33$28.66M1.67375,949 shs214,833 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDBVInvesco DB G10 Currency Harvest Fund0.00%0.00%0.00%0.00%0.00%EGRXEagle Pharmaceuticals0.00%+3.45%+33.33%+100.00%-45.45%HIPHAmer Prem Water0.00%0.00%0.00%0.00%0.00%PASGPassage Bio-6.07%+8.17%+2.41%+32.82%-52.73%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDBVInvesco DB G10 Currency Harvest FundN/AN/AN/AN/AN/AN/AN/AN/AEGRXEagle PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AHIPHAmer Prem WaterN/AN/AN/AN/AN/AN/AN/AN/APASGPassage Bio2.4246 of 5 stars3.53.00.00.00.01.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDBVInvesco DB G10 Currency Harvest Fund 0.00N/AN/AN/AEGRXEagle Pharmaceuticals 0.00N/AN/AN/AHIPHAmer Prem Water 0.00N/AN/AN/APASGPassage Bio 3.00Buy$7.501,632.10% UpsideCurrent Analyst Ratings BreakdownLatest HIPH, EGRX, DBV, and PASG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025PASGPassage BioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDBVInvesco DB G10 Currency Harvest FundN/AN/AN/AN/AN/AN/AEGRXEagle Pharmaceuticals$257.55M0.15$7.50 per share0.40N/A∞HIPHAmer Prem Water$70K0.00N/AN/AN/ANaNPASGPassage BioN/AN/AN/AN/A$0.99 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDBVInvesco DB G10 Currency Harvest FundN/AN/A0.00∞N/AN/AN/AN/AN/AEGRXEagle Pharmaceuticals$35.64MN/A0.00∞N/AN/AN/AN/AN/AHIPHAmer Prem WaterN/AN/A0.00N/AN/AN/AN/AN/AN/APASGPassage Bio-$64.77M-$1.02N/AN/AN/AN/A-93.59%-59.65%8/14/2025 (Estimated)Latest HIPH, EGRX, DBV, and PASG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025PASGPassage Bio-$0.24-$0.25-$0.01-$0.25N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDBVInvesco DB G10 Currency Harvest FundN/AN/AN/AN/AN/AEGRXEagle PharmaceuticalsN/AN/AN/AN/AN/AHIPHAmer Prem WaterN/AN/AN/AN/AN/APASGPassage BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDBVInvesco DB G10 Currency Harvest FundN/AN/AN/AEGRXEagle PharmaceuticalsN/AN/AN/AHIPHAmer Prem WaterN/AN/AN/APASGPassage BioN/A3.743.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDBVInvesco DB G10 Currency Harvest Fund85.24%EGRXEagle Pharmaceuticals85.36%HIPHAmer Prem WaterN/APASGPassage Bio53.48%Insider OwnershipCompanyInsider OwnershipDBVInvesco DB G10 Currency Harvest FundN/AEGRXEagle Pharmaceuticals28.90%HIPHAmer Prem WaterN/APASGPassage Bio4.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDBVInvesco DB G10 Currency Harvest Fund801.00 millionN/ANot OptionableEGRXEagle Pharmaceuticals10012.99 million9.23 millionNo DataHIPHAmer Prem Water164.40 billionN/ANot OptionablePASGPassage Bio13062.15 million59.48 millionOptionableHIPH, EGRX, DBV, and PASG HeadlinesRecent News About These CompaniesPassage Bio, Inc. (PASG) Income Statement - Yahoo FinanceJuly 1, 2025 | finance.yahoo.comPASG Passage Bio, Inc. - Seeking AlphaJune 27, 2025 | seekingalpha.comPassage Bio, Inc. (NASDAQ:PASG) Major Shareholder Orbimed Advisors Llc Sells 138,800 SharesJune 27, 2025 | insidertrades.comPassage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program UpdateJune 23, 2025 | globenewswire.comPassage Bio Reports Q1 2025 Financial Results and Highlights Progress in Gene Therapy DevelopmentMay 17, 2025 | msn.comPassage Bio : résultat d'exploitation de -16,459 millions de dollars au premier trimestreMay 13, 2025 | zonebourse.comZPASSAGE BIO, INC. : Wedbush persiste à l'achatMay 13, 2025 | zonebourse.comZPassage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business HighlightsMay 13, 2025 | globenewswire.comInsider Selling: Passage Bio, Inc. (NASDAQ:PASG) Major Shareholder Sells 68,195 Shares of StockApril 25, 2025 | insidertrades.comPassage Bio, Inc. (NASDAQ:PASG) Major Shareholder Orbimed Advisors Llc Sells 77,090 SharesApril 18, 2025 | insidertrades.comOrbiMed Advisors vend des actions de Passage Bio pour 49.704$April 18, 2025 | fr.investing.comL’action PASG atteint son plus bas niveau sur 52 semaines à 0,3$ face aux défis du marchéApril 8, 2025 | fr.investing.comL’action de Passage Bio chute à un plus bas de 52 semaines à 0,35$March 31, 2025 | fr.investing.comL'action Passage Bio chute à son plus bas niveau sur 52 semaines à 0,38$March 14, 2025 | fr.investing.comPassage Bio (PASG) Upgraded to Buy: Here's What You Should KnowMarch 7, 2025 | zacks.comPASSAGE BIO, INC. : Chardan Research reste à l'achatMarch 5, 2025 | zonebourse.comZL’action Passage Bio chute à son plus bas niveau sur 52 semaines à 0,45$March 5, 2025 | fr.investing.comPassage Bio price target lowered to $6 from $7 at ChardanMarch 5, 2025 | markets.businessinsider.comPassage Bio publie ses résultats du quatrième trimestre et de l'année 2024.March 4, 2025 | zonebourse.comZPassage Bio reports FY24 EPS ($1.07) vs ($1.86) last yearMarch 4, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHIPH, EGRX, DBV, and PASG Company DescriptionsInvesco DB G10 Currency Harvest Fund NYSEARCA:DBV$25.41 0.00 (0.00%) As of 03/10/2023PowerShares DB G10 Currency Harvest Fund (the Fund) is an index tracking fund and does not utilize any trading system, whether discretionary, systematic or otherwise. The Fund offers common units of beneficial interest (the Shares) only to certain eligible financial institutions (the Authorized Participants) in one or more blocks of 200,000 Shares, called a Basket. The Index is designed to reflect the return from investing on a 2:1 leveraged basis in long currency futures positions for certain currencies associated with relatively high yielding interest rates and in short currency futures positions for certain currencies associated with relatively low yielding interest rates. DB Commodity Services LLC serves as the managing owner, commodity pool operator and commodity trading advisor of the Fund.Eagle Pharmaceuticals NASDAQ:EGRX$3.00 +0.11 (+3.63%) As of 07/3/2025Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.Amer Prem Water OTCMKTS:HIPHAmerican Premium Mining Corporation focuses on supporting the blockchain ecosystem through proof-of-work and proof-of-stake mining of cryptocurrencies. The company was formerly known as American Premium Water Corporation and changed its name to American Premium Mining Corporation in May 2022. American Premium Mining Corporation is based in Playa Vista, California.Passage Bio NASDAQ:PASG$0.43 -0.03 (-6.11%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$0.45 +0.02 (+4.62%) As of 07/7/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
